Ishara Investments LP Purchases New Position in Agios Pharmaceuticals, Inc. $AGIO

Ishara Investments LP purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 4th quarter, HoldingsChannel reports. The firm purchased 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $817,000.

Several other large investors have also made changes to their positions in AGIO. AQR Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after buying an additional 2,920 shares in the last quarter. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals in the 1st quarter valued at approximately $40,000. Goldman Sachs Group Inc. grew its stake in shares of Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after buying an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in shares of Agios Pharmaceuticals in the 1st quarter valued at approximately $597,000.

Agios Pharmaceuticals Stock Performance

AGIO opened at $33.08 on Thursday. The business has a 50 day moving average price of $29.17 and a 200 day moving average price of $28.58. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00. The firm has a market cap of $1.97 billion, a P/E ratio of -4.56 and a beta of 0.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. The firm’s revenue for the quarter was up 137.7% on a year-over-year basis. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

AGIO has been the subject of several recent research reports. Bank of America lowered their price target on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, May 29th. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. HC Wainwright reduced their target price on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 20th. JPMorgan Chase & Co. reduced their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Thursday, June 11th. Finally, The Goldman Sachs Group boosted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $40.89.

Insiders Place Their Bets

In other news, insider Sarah Gheuens sold 2,940 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the transaction, the insider directly owned 80,277 shares in the company, valued at $2,786,414.67. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,848.80. Following the transaction, the insider owned 49,306 shares of the company’s stock, valued at approximately $1,711,411.26. This trade represents a 6.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 12,623 shares of company stock valued at $438,144 in the last three months. 5.40% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.